Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study

A. I. Dipchand, S. Webber, K. Mason, B. Feingold, C. Bentlejewski, W. T. Mahle, R. Shaddy, C. Canter, E. D. Blume, Jacqueline M. Lamour, W. Zuckerman, H. Diop, Y. Morrison, B. Armstrong, D. Ikle, J. Odim, A. Zeevi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Data on the clinical importance of newly detected donor-specific anti-HLA antibodies (ndDSAs) after pediatric heart transplantation are lacking despite mounting evidence of the detrimental effect of de novo DSAs in solid organ transplantation. We prospectively tested 237 pediatric heart transplant recipients for ndDSAs in the first year posttransplantation to determine their incidence, pattern, and clinical impact. One-third of patients developed ndDSAs; when present, these were mostly detected within the first 6 weeks after transplantation, suggesting that memory responses may predominate over true de novo DSA production in this population. In the absence of preexisting DSAs, patients with ndDSAs had significantly more acute cellular rejection but not antibody-mediated rejection, and there was no impact on graft and patient survival in the first year posttransplantation. Risk factors for ndDSAs included common sensitizing events. Given the early detection of the antibody response, memory responses may be more important in the first year after pediatric heart transplantation and patients with a history of a sensitizing event may be at risk even with a negative pretransplantation antibody screen. The impact on late graft and patient outcomes of first-year ndDSAs is being assessed in an extended cohort of patients.

Original languageEnglish (US)
JournalAmerican Journal of Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Heart Transplantation
Anti-Idiotypic Antibodies
Tissue Donors
Pediatrics
Incidence
Antibodies
Organ Transplantation
Graft Survival
Antibody Formation
Transplantation
Transplants
Population

Keywords

  • Clinical research/practice
  • Heart transplantation/cardiology
  • Monitoring: immune
  • Patient survival
  • Pediatrics
  • Rejection: acute
  • Rejection: antibody-mediated (ABMR)
  • Sensitization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation : A report from the CTOTC-04 study. / Dipchand, A. I.; Webber, S.; Mason, K.; Feingold, B.; Bentlejewski, C.; Mahle, W. T.; Shaddy, R.; Canter, C.; Blume, E. D.; Lamour, Jacqueline M.; Zuckerman, W.; Diop, H.; Morrison, Y.; Armstrong, B.; Ikle, D.; Odim, J.; Zeevi, A.

In: American Journal of Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

Dipchand, AI, Webber, S, Mason, K, Feingold, B, Bentlejewski, C, Mahle, WT, Shaddy, R, Canter, C, Blume, ED, Lamour, JM, Zuckerman, W, Diop, H, Morrison, Y, Armstrong, B, Ikle, D, Odim, J & Zeevi, A 2018, 'Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study', American Journal of Transplantation. https://doi.org/10.1111/ajt.14691
Dipchand, A. I. ; Webber, S. ; Mason, K. ; Feingold, B. ; Bentlejewski, C. ; Mahle, W. T. ; Shaddy, R. ; Canter, C. ; Blume, E. D. ; Lamour, Jacqueline M. ; Zuckerman, W. ; Diop, H. ; Morrison, Y. ; Armstrong, B. ; Ikle, D. ; Odim, J. ; Zeevi, A. / Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation : A report from the CTOTC-04 study. In: American Journal of Transplantation. 2018.
@article{fcb1c6c695944411b2626cd9f3cde41b,
title = "Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study",
abstract = "Data on the clinical importance of newly detected donor-specific anti-HLA antibodies (ndDSAs) after pediatric heart transplantation are lacking despite mounting evidence of the detrimental effect of de novo DSAs in solid organ transplantation. We prospectively tested 237 pediatric heart transplant recipients for ndDSAs in the first year posttransplantation to determine their incidence, pattern, and clinical impact. One-third of patients developed ndDSAs; when present, these were mostly detected within the first 6 weeks after transplantation, suggesting that memory responses may predominate over true de novo DSA production in this population. In the absence of preexisting DSAs, patients with ndDSAs had significantly more acute cellular rejection but not antibody-mediated rejection, and there was no impact on graft and patient survival in the first year posttransplantation. Risk factors for ndDSAs included common sensitizing events. Given the early detection of the antibody response, memory responses may be more important in the first year after pediatric heart transplantation and patients with a history of a sensitizing event may be at risk even with a negative pretransplantation antibody screen. The impact on late graft and patient outcomes of first-year ndDSAs is being assessed in an extended cohort of patients.",
keywords = "Clinical research/practice, Heart transplantation/cardiology, Monitoring: immune, Patient survival, Pediatrics, Rejection: acute, Rejection: antibody-mediated (ABMR), Sensitization",
author = "Dipchand, {A. I.} and S. Webber and K. Mason and B. Feingold and C. Bentlejewski and Mahle, {W. T.} and R. Shaddy and C. Canter and Blume, {E. D.} and Lamour, {Jacqueline M.} and W. Zuckerman and H. Diop and Y. Morrison and B. Armstrong and D. Ikle and J. Odim and A. Zeevi",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ajt.14691",
language = "English (US)",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation

T2 - A report from the CTOTC-04 study

AU - Dipchand, A. I.

AU - Webber, S.

AU - Mason, K.

AU - Feingold, B.

AU - Bentlejewski, C.

AU - Mahle, W. T.

AU - Shaddy, R.

AU - Canter, C.

AU - Blume, E. D.

AU - Lamour, Jacqueline M.

AU - Zuckerman, W.

AU - Diop, H.

AU - Morrison, Y.

AU - Armstrong, B.

AU - Ikle, D.

AU - Odim, J.

AU - Zeevi, A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Data on the clinical importance of newly detected donor-specific anti-HLA antibodies (ndDSAs) after pediatric heart transplantation are lacking despite mounting evidence of the detrimental effect of de novo DSAs in solid organ transplantation. We prospectively tested 237 pediatric heart transplant recipients for ndDSAs in the first year posttransplantation to determine their incidence, pattern, and clinical impact. One-third of patients developed ndDSAs; when present, these were mostly detected within the first 6 weeks after transplantation, suggesting that memory responses may predominate over true de novo DSA production in this population. In the absence of preexisting DSAs, patients with ndDSAs had significantly more acute cellular rejection but not antibody-mediated rejection, and there was no impact on graft and patient survival in the first year posttransplantation. Risk factors for ndDSAs included common sensitizing events. Given the early detection of the antibody response, memory responses may be more important in the first year after pediatric heart transplantation and patients with a history of a sensitizing event may be at risk even with a negative pretransplantation antibody screen. The impact on late graft and patient outcomes of first-year ndDSAs is being assessed in an extended cohort of patients.

AB - Data on the clinical importance of newly detected donor-specific anti-HLA antibodies (ndDSAs) after pediatric heart transplantation are lacking despite mounting evidence of the detrimental effect of de novo DSAs in solid organ transplantation. We prospectively tested 237 pediatric heart transplant recipients for ndDSAs in the first year posttransplantation to determine their incidence, pattern, and clinical impact. One-third of patients developed ndDSAs; when present, these were mostly detected within the first 6 weeks after transplantation, suggesting that memory responses may predominate over true de novo DSA production in this population. In the absence of preexisting DSAs, patients with ndDSAs had significantly more acute cellular rejection but not antibody-mediated rejection, and there was no impact on graft and patient survival in the first year posttransplantation. Risk factors for ndDSAs included common sensitizing events. Given the early detection of the antibody response, memory responses may be more important in the first year after pediatric heart transplantation and patients with a history of a sensitizing event may be at risk even with a negative pretransplantation antibody screen. The impact on late graft and patient outcomes of first-year ndDSAs is being assessed in an extended cohort of patients.

KW - Clinical research/practice

KW - Heart transplantation/cardiology

KW - Monitoring: immune

KW - Patient survival

KW - Pediatrics

KW - Rejection: acute

KW - Rejection: antibody-mediated (ABMR)

KW - Sensitization

UR - http://www.scopus.com/inward/record.url?scp=85044287702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044287702&partnerID=8YFLogxK

U2 - 10.1111/ajt.14691

DO - 10.1111/ajt.14691

M3 - Article

C2 - 29442424

AN - SCOPUS:85044287702

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -